Introduction
Glioblastoma (GBM) is the most frequent and malignant brain tumor in adults. Despite progress in surgical techniques, radiotherapy, chemotherapy and "target therapy" its prognosis remains poor (Brandes et al., 2009; Clarke et al., 2010; Louis et al., 2007) . Several biomarkers have been proposed as potentially useful parameters for prognosis, diagnosis or therapy strategies. Among them are microRNAs, or miRNAs, which are small (19e24nt) RNA strands with tissue-specific expression patterns and which play a functional role in several cellular processes involved in the tumorigenesis and progression of several neoplasia (such as proliferation, invasion, migration and angiogenesis). Due to their role in the regulation of gene expression, in the last few years miRNAs tissue-specific expression, quantification and functional analysis of miRNAs have been extensively investigated to understand their peculiar involvement in cellular processes. It is now established that each tissue has a characteristic micro-RNA expression pattern which could be altered in association with a number of different diseases including neoplastic transformation (Galasso et al., 2012; Nana-Sinkam and Croce, 2013; Zhang et al., 2007) . Nowadays, there are more than a hundred ongoing trials incorporating miRNAs as biomarkers (Nana-Sinkam and Croce, 2013) . For all these reasons miRNAs could represent important diagnostic, prognostic or predictive target molecules in the treatment of tumors (Galasso et al., 2012; Lawler and Chiocca, 2009; Nana-Sinkam and Croce, 2013; Zhang et al., 2007) .
In the last few years, several studies have been performed to identify a specific microRNA expression pattern of GBM (Chan et al., 2005; Ciafre et al., 2005; Conti et al., 2009; Dong et al., 2010; Gal et al., 2008; Godlewski et al., 2008; Guan et al., 2010; Hua et al., 2012; Lang et al., 2012; Loftus et al., 2012; Malzkorn et al., 2009; Niyazi et al., 2011; Rao et al., 2010; Sasayama et al., 2009; Silber et al., 2008; Skalsky and Cullen, 2011; Slaby et al., 2010; Srinivasan et al., 2011; Zhang et al., 2013; Zhou et al., 2010) . For example, recent works by LeBrun and Li (2011) and Mizoguchi et al. (2012) analyzed the results of many GBM miRNA profiling studies and underlined the adopted techniques, the source of neoplastic specimens and the type of non-neoplastic reference samples used in each study. Considering all profiling data, several discrepancies have been highlighted between different studies and a specific miRNA expression signature in GBM is far from being well-defined. These discrepancies could mainly be due to three factors in the experimental design: i) the technique performed to evaluate microRNA expression; ii) the starting material; iii) the choice of reference samples used in the analysis.
In a previous study we reported the feasibility of performing miRNA expression analysis using a real-time locked nucleic acid quantitative PCR (qRT-LNAPCR) starting from either fresh/frozen or formalin-fixed and paraffin-embedded (FFPE) GBM specimens . FFPE-dissected specimens were chosen as the most reliable material with which to perform a miRNA profiling study. In fact, starting from FFPE samples, a neoplastic cells enrichment step (microor macro-dissection) was feasible, FFPE samples could be easily retrieved from the archives of the Department of Pathology and furthermore the obtained results displayed good correlation values between miRNA expression and the corresponding fresh/frozen material . We have also shown that it is more advisable to compare miRNA expression data within similar experimental conditions because of the discrepancies observed among GBM miRNA profiles obtained using different non-neoplastic brain references .
Keeping in mind both the above considerations and the discrepant results sometimes encountered in literature between GBM miRNAs expression studies, in this study we validated the expression of 19 microRNAs in a group of GBM and described the signature of checked miRNAs, using three different non-neoplastic brain controls starting from FFPE tumor samples. Furthermore, we evaluated possible correlation between miRNA expression and methylation status of MGMT promoter and the putative targets of deregulated miRNAs. Moreover, we characterized gliomas of grades IeIII for the same panel of validated miRNAs to evaluate if some of them could be associated to a specific grade of malignancy.
2.
Materials and methods
Statement of ethics
The study was approved by Ethics Committee of Azienda Sanitaria Locale di Bologna (number of study 08075, protocol number 139/CE of 5th February 2009, Bologna, Italy). All patients signed a written consent for molecular analysis and anonymous data publication for scientific studies, and all information regarding the human material used in this study was managed using anonymous numerical codes. (Louis et al., 2007) . Thirty of these 60 cases were previously analyzed for the 19 miRNAs and represented our training set (Table 1 ). The 30 primary GBM belonged to testing set were 20 males and 10 females, aged from 41 to 78 years (mean age 61.7 yrs) ( Table 1 ).
The following primary brain tumors were also selected: 15 grade III (2 anaplastic ependymomas, 7 anaplastic oligodendrogliomas, 3 anaplastic astrocytomas, 3 anaplastic oligoastrocytomas; 10 males and 5 females, aged 30e74 years, mean 50.7 yrs), 15 grade II (2 ependymomas, 7 oligodendrogliomas, 1 pleomorphic xanthoastrocytoma, 1 diffuse astrocytoma and 4 neurocytomas; 11 males and 4 females, aged 21e74 years, mean 42.8 yrs) and 15 grade I (4 pilocytic astrocytomas and 11 gangliogliomas; 6 males and 9 females, aged 2e23 years, mean 20.8 yrs). All samples were diagnosed according to the 2007 WHO criteria (Louis et al., 2007) (Table 1) .
Non-neoplastic references
Fifteen "normal" tissues, adjacent to the tumor (8 males and 7 females, aged 50e75 years, mean 62.7 yrs), at a distance between 1 and 2 cm from the margin of 15 GBMs, were retrieved. Fifteen polar temporal cortical FFPE specimens, removed in patients submitted to surgery for drug-resistant epilepsy, were randomly selected from the archives of the Anatomic Pathology division of Bellaria Hospital (7 males and 8 females, aged 25e52 years, mean 39.7 yrs). Additionally, the FirstChoice Ò Human Brain Reference RNA was utilized (Ambion, Austin, TX, U.S.A).
Nucleic acid extractions
The haematoxylin and eosin (H&E) sections from FFPE specimens were reviewed by a pathologist (GM) to select the more informative block. One 10 mm-thick and four 20 mm-thick sections were cut, followed by one H&E control slide, for DNA and total RNA extractions respectively. The tumor area selected for the analysis was marked on the H&E section to ensure, whenever possible, greater than 90% content of neoplastic cells (avoiding necrosis and lymphocytes). Each section was manually dissected according to the selected area. DNA was extracted using QuickExtractä FFPE DNA Extraction Kit (Epicentre, Madison, WI, U.S.A.). miRNAs were extracted using RecoverAll Total Nucleic Acid Isolation kit (Ambion, Austin, TX, U.S.A.), according to manufacturer's instructions. SmallRNAs were quantified and cDNA obtained as previously described Visani et al., 2012) .
MicroRNAs analysis
19 miRNAs (miR-7, miR-9, miR-9*, miR-10a, miR-10b, miR-17, miR-20a, miR-21, miR-26a, miR-27a, miR-31, miR-34a, miR-101, miR-137, miR-182, miR-221, miR-222, miR-330, miR519d) , were selected for analysis, according to their role in cancer and data published in literature previous to the beginning of the study Visani et al., 2012) . Three smallRNAs (RNU49, U54, miR-103) were used as internal controls Visani et al., 2012) . The miRNA analyses were performed using real-time PCR as previously described Visani et al., 2012) . Briefly, RNA was retrotranscribed using the NCode miRNA FirstStrand cDNA Synthesis and qRT-PCR Kits (Invitrogen, Carlsbad, CA, USA), and miRNA expression was evaluated on the AB7000 machine (Applied Biosystem, Foster City, CA, USA) performing a miRNA-specific real-time qPCR using LNA primers Visani et al., 2012) .
2.5.
Validation of the 19 miRNA expression signature in the testing set
The expression of the 19 miRNAs was evaluated in the testing set (n ¼ 30 GBMs) and the values compared with those obtained in the training group (n ¼ 30 GBMs). In order to define expression values of the analyzed miRNAs in GBM reducing possible biases due to reference selection, only microRNAs with the same regulation status in at least 2 out of the 3 profiles in both groups were considered. 
2.6.
MGMT methylation and IDH1 mutation analysis
MGMT analysis
At least 50 ng of DNA were treated with bisulfite using the EpiTect Bisulfite kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. A Methylation Sensitive RealTime qPCR using LNA modified primers and beacon probes (MS-qLNAPCR) was performed as previously described (Morandi et al., 2010 ).
IDH1 analysis
Tumor samples were tested for the IDH1-R132H mutation using Allele-Specific Locked Nucleic Acid quantitative PCR (ASLNAqPCR) . To put briefly, allele-specific primers that recognized the IDH1 wild-type sequence or the R132H mutation were designed using Primer3 software (http://frodo.wi.mit.edu/primer3/). Both forward primers were designed with 3 0 -locked nucleic acid (LNA e underlined nucleotides within the primer sequences) substitutions to improve mismatch discrimination ( 
Statistical analysis
Expression values and fold changes were obtained by relative quantification and 2 ÀDDCT method (Livak and Schmittgen, 2001 ) using DataAssist v3.01 Tool (Applied Biosystem, Foster City, CA, USA). The unsupervised hierarchical clustering analysis (Pearson Correlation, average linkage) was performed using the same statistical tool. Statistical analysis of miRNA expression was performed using GraphPad Prism 5.0 software. Correlation analysis between the different groups was performed applying Spearman correlation test. For comparing the expression levels of each miRNA between different groups, ManneWhitney test was used. Gaussian distribution was evaluated by ShapiroeWilk Test. A microRNA was considered as down-regulated with a median fold change (FC) < À2.0, while a microRNA with a median FC ! 2.0 was considered as up-regulated.
Level of significance was p < 0.05 for all statistical analyses. For microRNA target analyses, a statistical overrepresentation test (Cho and Campbell, 2000) was performed using PANTHER web tool (http://www.pantherdb.org/tools/ uploadFiles.jsp). The list of target genes was compared to a reference list to statistically determine over-or under-representation of PANTHER classification categories. p-values were calculated with Bonferroni correction; a cut-off of 0.05 was considered to estimate if a specific PANTHER category was over-or under-represented in a statistically significant way.
Bioinformatic prediction of microRNA targets
The experimentally-validated targets of microRNA which were significantly deregulated in the GBM profile were identified using three different online tools: miRecords (http://mirecords.umn.edu/miRecords/) (Xiao et al., 2009) , miRTarBase (http://mirtarbase.mbc.nctu.edu.tw) (Hsu et al., 2011) and miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/ mirwalk) (Dweep et al., 2011) . The latest releases of miRecords (http://mirecords.umn.edu/miRecords/download.php, updated on November 25th, 2010) and miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/php/download.php, "hsa MTI.xls" file, release 3.5 of November 1st, 2012) were downloaded and only microRNAs of interest were selected. The list of selected microRNAs was uploaded on miRWalk "Validated target(gene) of mirna search" section (http://www.umm.uni-heidelberg.de/ apps/zmf/mirwalk/mirnatargetpub.html, updated on March 11th, 2011) to obtain the list of experimentally-validated targets relative to each microRNAs of interest. Only targets identified by all 3 prediction tools were then considered. Targets were analyzed and grouped according to their molecular functions, biological process involvement and pathways classification, using the PANTHER web tool (http://www.pantherdb.org/) (Mi et al., 2013) .
Results

Validation of the 19 miRNA expression signature in the testing set
Considering that microRNA was considered as downregulated with a median fold change (FC) < À2.0, while a microRNA with a median FC ! 2.0 was considered as upregulated, the expression status of the 19 miRNAs in the testing set (n ¼ 30) was compared with those of training group (Table 2 ). According to this comparison, 14 miRNAs (miR-7, miR-9*, miR-10a, miR-10b, miR-17, miR-21, miR-31, miR-34a, miR-101, miR-137, miR-182, miR-221, miR-222 and miR-330) showed the same regulation status between the two groups. Only these 14 miRNAs were then considered for further analysis.
Expression signature of the 14 validated miRNAs in GBMs
Three different profiles were obtained comparing the 14 validated miRNAs in the entire cohort of 60 GBMs toward the three different non-neoplastic control groups (normal tissues adjacent to the tumor, epileptic specimens, and a commercial reference). The median expression values of the 14 miRNAs in the GBMs are shown in Suppl. Table 1 . 6 miRNAs (miR-7, miR-31, miR-101, miR-137, miR-222 and miR-330) were downregulated (Table 3, Suppl. Table 1 ). All miRNAs with a FC < À2 were down-regulated in at least 50% of analyzed glioblastoma (Table 3, Suppl. Table 1) .
Two microRNAs (miR-10b and miR-21) were up-regulated in GBM group (Table 3, Suppl. Table 1 ). All miRNAs with a FC ! 2 were also up-regulated in at least 50% of analyzed GBM cases (Table 3 , Suppl. Table 1 ).
Six microRNAs (miR-9*, miR-10a, miR-17, miR-34a, miR-182 and miR-221) showed expression levels that were within the 2 fold cut-off and for this reason were considered to not be deregulated (Suppl. Table 1 ).
The power of the study was calculated considering 70% of GBM deregulated for validated miRNAs and hypothesizing to observe at least 85% of cases with these miRNAs deregulated in our final cohort of 60 GBMs. According to these parameters the power of the study was 0.77.
An unsupervised hierarchical cluster showed that considering these 14 miRNAs, GBM clustered together if compared with to non-neoplastic references (Suppl. Figure 1) .
Correlation between the GBM miRNA signatures obtained with the three non-neoplastic references were evaluated using the Spearman correlation test (Table 4) . A high correlation (>0.65) value (r ¼ 0.859 or r ¼ 0.899) was observed in all the comparisons (Table 4) . Expression values obtained using commercial reference and adjacent to the tumor samples as nonneoplastic controls showed the higher number of miRNAs (n ¼ 11) with the same regulation status ( 
3.3.
Comparison between MGMT methylated and unmethylated GBM samples Twenty-seven out of 59 analyzed cases (45.8%) showed methylation of the MGMT promoter. All cases were wildtype for IDH1, supporting the classification of "primary GBM" (Yan et al., 2009) (Table 5 ). In one case, MGMT and IDH1 analysis were not evaluable, probably due to poor quality of extracted DNA.
Considering the variation of expression of the 14 miRNAs validated in GBM profiles, an unsupervised hierarchical clustering analysis was performed to compare MGMT methylated (MET, n ¼ 27) and unmethylated (UMET, n ¼ 32) samples. The results indicated that there was not a significant correlation between methylation status of MGMT promoter and micro-RNA expression: considering this subset of microRNAs, METeGBM and UMETeGBM groups did not show a clear clusterization, regardless of the selected non-neoplastic reference (Suppl. Figure 1) . Moreover, the median expression values for each miRNA showed no differences between METeGBM and UMETeGBM groups irrespective of the control groups used (data not shown). 12 miRNAs showed no differences in regulation status between METeGBM and UMETeGBM groups. MicroRNA-182 was up in UMETeGBM samples but not deregulated in METeGBM; miR-221 was down-regulated in UMETeGBM but not deregulated in METeGBM (data not shown).
3.4.
Analysis of putative microRNA targets
To further investigate the biological relevance of the determined GBM miRNA profile, we looked for the known targets of the 8 significantly deregulated microRNAs (Table 3 ). The analysis was focused on the research of targets experimentally validated in previously published studies. Among available bioinformatics tools online, miRecords, miRTarBase and miRWalk were used. Considering the 8 microRNAs, 81 validated targets on miRecords (http://mirecords.biolead.org/) and 174 on miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/) were found, noting that both tools consider manually- performed experimental interactions based on literature surveying. Using miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/), based on automated textmining search, 560 targets were found. Combining these results, 46 genes were found in common to the three target prediction databases (Suppl. Table 2 ). This gene list was entered into the PANTHER database in order to identify significantly over-and under-represented pathways, molecular functions and biological processes, in comparison with a reference list (the default Homo Sapiens Whole Genome list was selected) (Table 6 ). From the initial list of 46 genes, PANTHER was unable to map the gene KLF4. For this reason all analyses were performed on a total of 45 gene targets. In Table 6 , statistically significant ( p < 0.05) pathways, molecular function classes and biological processes relevant to the 45 gene targets were listed. In all cases, a statistically significant overrepresentation of the number of target genes per category was observed.
MicroRNA expression analysis in grades IeIII brain tumors
To evaluate possible differences in miRNA expression associated with different grade of malignancy, we further analyzed the miRNA profiles in grades IeIII brain tumors (Suppl. Table  3 ). Considering that normal tissue adjacent to the tumor tissues were not available for grades IeIII brain tumors, Ambion and epileptic tissue groups were used for the analysis of miRNAs profile in these samples (Table 7) . For this reason, we focused our attention on the 9 miRNAs with the same GBM expression profile with commercial and epileptic control groups (miR-7, miR-9*, miR-10b, miR-17, miR-21, miR-34a, miR-101, miR-137 and miR-222) (Suppl. Table 1 ). As happened for GBM analysis, the up-(FC ! 2) or down-regulated (FC < À2) miRNAs were deregulated in at least the 50% of analyzed samples (Suppl. Table 3 ).
Grade I (Table 7 , Suppl. Table 3) : miR-7, miR-10b, miR-137 and miR-222 were observed as down-regulated (miR-222 only according to the epileptic tissues); miR-21 and miR-34a were up-regulated. Grade II (Table 7 , Suppl. Table 3) : miR-7, miR-10b, miR-137 and miR-222 were observed as down-regulated (miR-10b only considering the commercial reference); miR-34a was upregulated. Grade III (Table 7 , Suppl. Table 3) : miR-7, miR-101, miR-137 and miR-22 were down-regulated; miR-10b and miR-21 were upregulated (miR-21 only against epileptic tissues).
Spearman correlation between the four tumor groups (grades IVeI) showed a high (>0.65) correlation value 
(r ¼ 0.9167) between high-grade gliomas (grades IV and III) considering the Ambion commercial reference; using the epileptic tissues as controls the highest values were observed and between high-grade gliomas (grades IV and III) (r ¼ 0.8833) and between low-grade gliomas (r ¼ 0.9333) (Suppl. Table 4 ). An unsupervised hierarchical clustering analysis showed that there was not a distinct clustering between differentgrade gliomas, both using Ambion commercial reference or epileptic group as controls (data not shown).
Comparing microRNA expression analysis between grades IeIV brain tumors
The different regulation statuses of miRNAs among the four tumor groups were evaluated. miR-9* and miR-17 were not deregulated in any analyzed profiles (Table 7) .
3 microRNAs (miR-10b, miR-34a, miR-101) shared the same deregulation status in high-grade gliomas (grades III and IV): miR-34a was not deregulated in high-grade gliomas but was up-regulated in low-grade (grades I and II) tumors (Figures 1  and 2 and Table 7 ); miR-101 was down-regulated in high grade (III and IV) but not in low-grade (I and II) gliomas (Figures 1 and  2 and Table 7 ); miR-10b was up-regulated in high-grade gliomas (III and IV) and meanwhile was significantly downregulated in low-grade (I and II) brain tumors ( p < 0.001) (Figures 1 and 2 and Table 7 ). This last microRNA was downregulated or not deregulated in grade II depending on the non-neoplastic reference (Figures 1 and 2 and Table 7 ).
3 microRNAs (miR-7, miR-137 and miR-222) were downregulated in all glioma groups even with observed significant differences in expression levels (e.g. between GBM and grade II for miR-7 e p < 0.01, or between GBM and grade I for miR-137 e p < 0.001, Figures 1 and 2 and Table 7 ). MicroRNA-222 was down-regulated or not deregulated in grade I depending on the non-neoplastic reference (Figures 1 and 2 and Table 7) . miR-21 was up-regulated in grade IV and in grade I tumors, but it was not deregulated in those of grade II (Figures 1 and 2 and Table 7 ). In grade III, miR-21 showed up-regulation only when compared with the epileptic reference (Figures 1 and 2 and Table 7 ).
Discussion
Bearing in mind that in GBM the surgery, radio-and chemotherapies are not enough to combat tumor progression and to ensure a hopeful outcome, the identification of a specific pattern of expression of miRNAs in GBM could provide an important boost in prognosis definition and in new target therapy strategies. Presently, several miRNA profiles are available for GBM (Chan et al., 2005; Ciafre et al., 2005; Conti et al., 2009; Dong et al., 2010; Gal et al., 2008; Godlewski et al., 2008; Guan et al., 2010; Hua et al., 2012; Lang et al., 2012; Loftus et Pathways, molecular function classes and biological processes resulted significantly over or under represented by 46 gene targets. a Number of genes in the reference list that map to this PANTHER classification category. b Number of genes in the target genes list that map to this PANTHER classification category. c Expected value is the number of genes that could be expected in target genes list for this PANTHER category based on the reference list. d Percentage of genes in the target list out of the total considered genes in PANTHER (n=45). P-values are determined by binomial statistics with Bonferroni correction: a p-value cut-off of 0.05 was considered.
and Cullen, 2011; Slaby et al., 2010; Srinivasan et al., 2011; Zhang et al., 2013; Zhou et al., 2010 ) and a small subset of consistently deregulated miRNAs was further functionally characterized for their activities and downstream targets possibly involved in the tumor (Chen et al., 2008; Huse et al., 2009; Kefas et al., 2008; Li et al., 2011; Sasayama et al., 2009; Smits et al., 2010) . However, due to several differences in the study designs, a clear miRNA profile for GBM has not been established yet. Considering the data previously obtained by our group Visani et al., 2012) , in this study the expression of 19 miRNAs in GBM was analyzed, starting from FFPE-dissected samples to ensure a good enrichment in neoplastic cells . Three different nonneoplastic references were enrolled for the analysis, to verify if different controls could influence GBM microRNAs expression values. Fourteen out of these 19 miRNAs showed the same deregulation status between training and testing sets and for this reason considered for further analysis. According to adopted non-neoplastic references, differences in the median expression values of the 14 validated microRNAs in GBM were observed. Furthermore, different fold-change values were observed even in those miRNAs with the same regulation status between all three profiles (e.g. miR-7, miR-137).
To better define a GBM microRNA signature, only validated microRNAs deregulated in at least 2 out of the 3 profiles obtained were considered. According to our results, 2 miRNAs (miR-10b and miR-21) were up-regulated and 6 miRNAs (miR-7, miR-31, miR-101, miR-137, miR-222 and miR-330) were down-regulated in group of 60 GBMs.
The microRNA GBM signature found in the present series was in accordance with profiling data previously reported in literature, except for miR-222 that was down-regulated in our series. Although miR-221 and miR-222 are encoded in the same genomic cluster on the X chromosome (http:// www.ncbi.nlm.nih.gov/gene/, Genes ID: 407006 and 407007), miR-221, differently than miR-222, was not deregulated. Several studies reported an up-regulation of miR-221/222 cluster in GBM (Ciafre et al., 2005; Quintavalle et al., 2012; Zhang et al., 2010) . Quintavalle et al. (2012) and Zhang et al. (2010) assessed the up-regulation of miR-222 in GBM cell lines in comparison with non-tumorigenic cell line or the commercial reference. On the contrary, in the present study, we evaluated the regulation of miRNAs in surgical GBM specimens and not in cell lines by using three different non-neoplastic controls. Ciafre et al. (2005) analyzed miR-221 in fresh/frozen samples and miR-222 in cell lines. In these situations, the discrepancies observed with our data could be due to the differences in starting material used for establishing microRNA expression.
The down-regulation of miR-221 and miR-222 status was previously observed by Slaby et al. and Lakomy et al. using stem-loop RT-PCR in FFPE-dissected GBMs (ensuring >90% of tumor cells) in comparison to non-malignant brain tissues, derived from areas surrounding arteriovenous malformation (AVM) or from commercial reference (Slaby et al., 2010; Lakomy et al., 2011) . Slaby et al. (2010) explained this downregulation was due to the choice of normal brain samples that could lead to discrepant results with data obtained in other studies.
The differences observed in the expression of miRNAs belonging to the same genomic cluster (miR-221 and miR- Ambion commercial reference/epileptic group were used as non-neoplastic controls. a p-value is calculated according to Mann-Whitney test versus grade IV profile. b Using the 2 different references, commercial reference/epileptic tissues, a different regulation status was observed. UP: up-regulated; DOWN: down-regulated; =: not deregulated; ns: not statistically significant. * p<0.05, ** p<0.01, *** p<0.001. 222) could be due to post-transcriptional modification, as described, for example, by Davis et al. (2009) .
According to our panel, only 2 miRNAs (miR-182 and miR-221) showed a different regulation status between methylated and unmethylated samples. MicroRNA-221 was previously described as mechanism of post-transcriptional regulation of MGMT (Quintavalle et al., 2013) . On the contrary, to the best of our knowledge, a possible correlation between miR-182 and MGMT methylation status has not been previously described in literature.
Taking into account the 8 microRNAs (miR-7, miR-10b, miR-21, miR-31, miR-101, miR-137, miR-222 and miR-330) showing a deregulation in GBMs, a preliminary analysis of their experimentally-validated targets was performed. Forty-six targets, shared by three bioinformatics tools, were further analyzed for their molecular function and pathway involvement: interleukin signaling, insulin/IGF pathway-MAPKK/MAPK cascade, gonadotropin-releasing hormone receptor (GNRHR), angiogenesis and Insulin/IGF-PKB pathways were significantly represented by this list of targets and previous studies have demonstrated their decisive role in GBM pathogenesis (Bulnes et al., 2012; de la Iglesia et al., 2008; Ermoian et al., 2002; Low et al., 2008; Montagnani Marelli et al., 2009; Nakada et al., 2011; Trojan et al., 2007; van Groeninghen et al., 1998; Wang et al., 2012) . The expression of the 9 miRNAs (miR-7, miR-9*, miR-10b, miR-17, miR-21, miR-34a, miR-101, miR-137, miR-222) with consistent regulation status in GBM using Ambion reference or epileptic tissues, was also investigated in lower grade tumors (grades IeIII), to evaluate if there were relevant differences associated with different grades of malignancy. Only 3 microRNAs (miR-7, miR-137 and miR-222) showed the same deregulation status in all four tumor grades. Nonetheless, some significant differences in miRNAs expression levels were observed between the groups.
In spite of the power of the study below 0.8 (0.77) and the awareness that a higher number of GBM should be preferable for more accurate results, it should be considered the distinctiveness and uniformity of our cohort, composed of 60 highly selected GBM. In fact all patients were resident in the same geographical region (Emilia-Romagna) and were surged by the same surgical teams, all diagnoses were obtained with a consensus between neuropathologists and all GBM were primary tumors. All these criteria were chosen for having a homogeneous cohort of specimens and limiting bias of results due to study design.
The unsupervised hierarchical clustering analysis showed that there was no distinct clusterization between differentgrade gliomas. This might suggest that the entire panel of these 9 microRNAs is unsuitable for discriminating gliomas based on the grade of malignancy.
Figure 2 e Differences in miRNA expressions among the 4 different-grade tumor groups was evaluated using the epileptic group as control. Box plots show microRNAs different between GBM Group (grade IV) and the other 3 tumor groups. Y-axis indicates the microRNA Log 10 expression level: "Up" and "Down" lines highlight the cut-off of 2 fold change used to consider a microRNA as deregulated. In bold are the up-or downregulated median FC values. Bars mean minimum and maximum values of miRNAs. *p < 0.05, **p < 0.01, ***p < 0.001 according to ManneWhitney test. FC: median Fold Change.
Intriguingly, 3 microRNAs shared the same deregulation status in high-grade gliomas (grades III and IV): miR-34a, miR-101 and miR-10b. miR-34a, stable in high-grade tumors, was on the other hand up-regulated in low-grade gliomas (grades I and II); this miRNA was previously reported to be down-regulated in GBM and its possible role in GBM pathogenesis was investigated (Genovese et al., 2012; Li et al., 2009; Silber et al., 2012) . Oncogenes like c-met, Notch1, Notch2, CDK6, PDGFRA and SMAD4, in TGFb/SMAD pathway, were validated as targets of miR-34a and they were effectively overexpressed in GBM (Genovese et al., 2012; Li et al., 2009; Silber et al., 2012) . Although miR-34a was not deregulated in our high-grade glioma groups, it showed an up-regulation in low-grade tumors, suggesting a possible association between miR-34a loss of expression and pathogenesis of high-grade glial neoplasias.
miR-101 was down-regulated in high grade but not in lowgrade gliomas, and this result is in accord with previously published studies (Silber et al., 2008; Smits et al., 2010) . In particular, we discovered that miR-101 down-regulation is present only in association with high-grade malignancy. Smits et al. (2010) have previously demonstrated one possible role of miR-101 in GBM progression; they obtained lower levels of miR-101 in comparison with grades II and III gliomas and they reported the association with over-expression of miR-101 target EZH2, which influences proliferation, invasion and angiogenesis.
miR-10b was up-regulated in high-grade gliomas while was significantly down-regulated in low grade ones. The data concerning GBM is in-line with results previously published by other studies (Ciafre et al., 2005; Gabriely et al., 2010; Sasayama et al., 2009; Silber et al., 2008) . In particular, Gabriely et al. (2010) demonstrated the role of miRNA-10b in cell proliferation and in cell cycle regulation by targeting Bim (a pro-apoptotic factor), p16/CDKN2A and p21/CDKN1B. Additionally, the study by Sasayama et al. (2009) reported that levels of invasive factors RhoC and urokinase-type plasminogen activator receptor (uPAR) were inversely correlated with miR-10b expression, indicating that it might play a key role in invasion features of gliomas. They reported that miR-10b expression was associated with glioma grade of malignancy and its expression was significantly lower in low-grade gliomas compared to high-grade astrocytic tumors (Sasayama et al., 2009 ). All of this data has suggested that the silencing of miR10b could be a potential therapeutic strategy for GBM treatment. An analysis of miR-10b expression in primary lowgrade gliomas and in corresponding secondary GBM lesions could be useful to evaluate a possible correlation with tumor progression. It should be considered that the present series of low-grade gliomas were heterogeneous groups. Further studies are necessary for determining specific differences between GBM and different histotypes of low-grade brain tumors.
In conclusion, we determined a GBM microRNA profile and performed a comparison of selected miRNAs in differentgrade gliomas. Beyond these results, one of the main conclusions of our study is that GBM microRNA profiling studies should be compared considering similar experimental conditions (i.e. the number of cases analyzed, the type of selected tissue, the non-neoplastic control chosen and the technique adopted for microRNA expression analysis).
Bearing in mind these considerations, further investigations such as extensive sequencing of miRNAs in a vast group of GBM or the analysis of miRNA expression in low-grade primary glioma tumors and in their corresponding secondary high-grade lesions, could be critical to discover new therapeutic strategies and possible correlations with glioma progression.
